Insider buying last 90 days
No open-market insider purchases were filed for RGEN in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every RGEN insider filing, plotted on the chart in Gekko.Open RGEN in Gekko
NASDAQ: RGEN
Repligen (RGEN) Stock Analysis & Forecast
Sep 28 close
$194.09+4.41 (+2.3%)
Gekko Brief
AI summaryRepligen touched a new 52-week high this week, trading as high as $198.87, with coverage attributing the move to strong financial performance and investor confidence. Alongside the price strength, CEO Olivier Loeillot filed several insider transactions, including a sale of 12,946 shares valued at approximately $2.46 million under a Rule 10b5-1 trading plan, concurrent with an option exercise valued at about $2.01 million, along with an earlier sale of 5,426 shares for $976,680 paired with an option exercise for $769,352.
Shares closed at $194.09, up 2.3%, sitting above both the 50-day average of $165.95 and the 200-day average of $143.00, with the 50-day above the 200-day. The GekkoIndex reads 45.8, placing RGEN in the Neutral zone, down 6.1 over the past five sessions. Price sits 23.8% above Gekko Fair Value of $156.83. One-month return stands at 6.6%, three-month at 41.7%, and six-month at 76.3%.
The next earnings report is due 3 November 2026, before the open, 35 days out and beyond a typical 20-trading-day hold; the prior report on 28 July topped estimates, with EPS of $0.54 against a $0.45 estimate and a 7.8% reaction, and the company has beaten in 6 of the last 8 quarters. Seasonality over the next 20 trading days has averaged -2.6% across 5 years, rising in only 1 of them. No insider, Congress, or unusual options activity appears in the current window, while one billionaire holder and two trailblazer holders are recorded. Analyst consensus stands at 11 buy and 1 hold ratings across 12 firms, with a consensus target of $189.48.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
Repligen price vs fair value
Close $194.09200-day averageGekko Fair Value $156.83
Repligen quick facts
- Market cap
- $10.95B
- P/E ratio
- 250.9
- Forward P/E
- 67.1
- EPS, TTM
- $0.76
- Revenue, TTM
- $785.1M
- Profit margin
- 5.3%
- Dividend yield
- —
- Beta
- 1.05
- Volume
- 1.57M avg 1.07M
- 1-year return
- +59.5%
- Typical daily move
- ±3.4%
- Typical 20-day move
- ±7.7%
- 50-day average
- $165.95
- 200-day average
- $143.00
- Next earnings
- Nov 3 before open
- Shares outstanding
- 56.44M
Repligen swing-trade checklist
Repligen scores 2 supportive, 1 mixed and 2 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive1 mixed2 headwinds
- Trendsupportive
Above 50 and 200-day
Close $194.09 is above the 50-day ($165.95) and 200-day ($143.00) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
45.8, Neutral
Reading 45.8 is in the Neutral zone.
See the GekkoIndex - Fair valueheadwind
23.8% above
Price is 23.8% above Gekko Fair Value (more than 5% above).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 35 days
Next report Nov 3, 2026, 35 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalityheadwind
−2.6% on average
From this point in the calendar, the next 20 trading days averaged −2.6% over 5 years, rising in 1 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Repligen stock chart and price history
Repligen closed at $194.09 on Sep 28, 2026, +59.5% over the past year, inside a 52-week range of $100.99 to $198.87.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +6.6%
- 3 months
- +41.7%
- 6 months
- +76.3%
- 1 year
- +59.5%
The full RGEN chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open RGEN in Gekko
Follow Repligen through every session
Put RGEN on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track RGEN in GekkoFree for 7 days. No credit card required.
About Repligen
Repligen builds tools and equipment that support the manufacture of biologic drugs, covering several steps of that process. Among its best known items are Protein A ligands used inside affinity chromatography resins, along with its OPUS pre-packed columns for purifying biologics and smaller OPUS formats used for screening, viral clearance testing and scaled-down purification work. The company also makes ELISA kits, CaptivA-branded resins, and a wide range of filtration gear including XCell Alternating Tangential Flow units, TangenX flat sheet cassettes, KrosFlo tangential flow and depth filtration systems, Spectra/Por dialysis products, SpectraFlo dialysis units, ProConnex single-use hollow fibers, and spectroscopy instruments sold as SoloVPE, FlowVPE and FlowVPX.
Its customer base spans life sciences groups, biopharma and diagnostics firms, academic and industry researchers, and contract manufacturers, with sales reaching organizations in North America, Europe, Asia Pacific and elsewhere. Repligen also teams up with outside firms, among them Navigo Proteins GmbH, to jointly develop affinity ligand technology.
The company traces back to 1981 and runs its headquarters out of Waltham, Massachusetts. Its stock trades on the NASDAQ under the ticker RGEN.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- repligen.com
Repligen GekkoIndex: the smart money zone
Repligen’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 45.8, in the Neutral zone, down 6.1 points over five sessions.
45.8Neutral
Down 6.1 points over five sessions.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 48 | −0.6% | −3.0% | ||
| Accumulation | 219 | +1.2% | +2.6% | ||
| Neutral (current zone) | 369 | −0.2% | 0.0% | ||
| Distribution | 35 | +0.1% | −2.6% | ||
| Selling | 1 | Too few readings yet | |||
Average RGEN share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the RGEN price, zone by zone.Track RGEN in Gekko
Is Repligen stock overvalued? Gekko Fair Value
Repligen trades 23.8% above Gekko Fair Value of $156.83, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what Repligen shares are worth, recalculated every trading day.
$156.83
Gekko Fair Value, Sep 26, 2026
23.8% Overvalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open RGEN in Gekko
Repligen insider and Congress trading
No open-market insider purchases were filed for Repligen, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in RGEN were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for RGEN, plotted on the chart in Gekko.Open RGEN in Gekko
Buybacks
Repligen has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $1.07M
- As a share of market cap
- 0.01%
From company filings.
Hedge funds and billionaires quarter ended Jun 30
3of the funds Gekko tracks hold RGEN.
2added1opened0trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko
Repligen earnings: next date and track record
Repligen reports on Nov 3, 2026, before the open (35 days away), and beat the EPS estimate in 6 of its last 8 reports.
Next earnings report
Nov 3, 2026
Expected before the open, 35 days away
- EPS estimate
- $0.46
- Revenue estimate
- $206.8M
6 of 8reports beat the EPS estimate
±5.6%average move across the report
5 of 8reports followed by a gain
Share-price move across each report
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Jul 28, 2026 | $0.54 est $0.45 | $204.1M est $201.6M | +7.8% |
| May 5, 2026 | $0.48 est $0.39 | $194.3M est $192.1M | +6.4% |
| Feb 24, 2026 | $0.49 est $0.44 | $197.9M est $192.9M | −2.4% |
| Oct 28, 2025 | $0.46 est $0.42 | $188.8M est $192.2M | −7.8% |
| Jul 29, 2025 | $0.37 est $0.40 | $182.4M est $181.8M | +2.7% |
| Apr 29, 2025 | $0.39 est $0.35 | $169.2M est $173.6M | −3.9% |
| Feb 20, 2025 | $0.44 est $0.42 | $167.5M est $164.1M | +5.5% |
| Nov 12, 2024 | −$0.01 est $0.33 | $154.9M est $153.0M | +7.9% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Repligen stock forecast and analyst price targets
Analysts’ average 12-month price target for Repligen is $189.48, −2.4% from the last close, from 12 firms rating the stock in the last 90 days.
$189.48consensus 12-month target, −2.4% from the last close
Now $194.09Avg $189.48
Low $145High $225
Each firm’s latest rating in the last 90 days: 12 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 25 | Craig-Hallum | — | — |
| Sep 15 | Stifel Nicolaus | — | — |
| Sep 9 | UBS | $225 | +15.9% |
| Aug 16 | Wells Fargo | $185 | −4.7% |
| Jul 30 | Wells Fargo | $185 | −4.7% |
0.0%average 20-day move after past Neutral readings
−2.6%average move over the next 20 trading days in the last 5 years
±3.4%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Repligen seasonality: the next 20 trading days
Over the next 20 trading days from Sep 29, Repligen averaged −2.6% across the last 5 years, rising in 1 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +3.8% | 2 of 5 |
| Next 10 trading days | +0.7% | 2 of 5 |
| Next 15 trading days | +0.1% | 2 of 5 |
| Next 20 trading days | −2.6% | 1 of 5 |
| Next 30 trading days | −0.4% | 1 of 5 |
For scale, RGEN’s typical 20-trading-day move in either direction is about 7.7%.
Repligen market cap and key statistics
Repligen’s market cap is $10.95B, with a P/E ratio of 250.9 and revenue of $785.1M over the last twelve months.
Valuation
- Market cap
- $10.95B
- P/E ratio
- 250.9
- Forward P/E
- 67.1
- EPS, TTM
- $0.76
- Gekko Fair Value
- $156.83
Trading
- Volume
- 1.57M
- Avg volume, 20 days
- 1.07M
- 52-week high
- $198.87
- 52-week low
- $100.99
- Shares outstanding
- 56.44M
Financials
- Revenue, TTM
- $785.1M
- Profit margin
- 5.3%
- Return on equity
- 2%
- Quarterly earnings growth, YoY
- −65.9%
Risk and income
- Beta
- 1.05
- Typical daily move
- ±3.4%
- Typical 20-day move
- ±7.7%
Repligen stock news this week
Coverage of Repligen this week reads neutral: 1 positive, 7 neutral and 2 negative headlines.
- Form 4 Repligen Corporation For: 27 September By Investing.comInvesting.com Australia, Sep 27
- Repligen CEO Olivier Loeillot sells $976,680 in company stock By Investing.comInvesting.com South Africa, Sep 27
- Repligen CEO Loeillot sells $2.46m in sharesInvesting.com, Sep 26
- Form 4 Repligen Corporation For: 26 SeptemberInvesting.com India, Sep 26
- Repligen Corp (RGEN) CEO Olivier Loeillot Sells 12,946 SharesGuruFocus, Sep 26
- Repligen (RGEN) CEO sells shares at $190 each after exercising options under a trading plan.Stock Titan, Sep 25
Repligen peers
Repligen’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 17.9% above |
| JNJJohnson & Johnson | Neutral | 0.5% above |
| ABBVAbbVie | Neutral | 23.3% above |
| MRKMerck | Neutral | 4.2% below |
| AZNAstraZeneca | Neutral | 39.9% below |
| PFEPfizer | Neutral | 4.0% below |
A peer links to its own page where one exists.
Repligen stock FAQ
What is Repligen’s market cap?
Repligen’s market cap is $10.95B at the Sep 28, 2026 close of $194.09, with 56.44M shares outstanding. The shares trade on a P/E ratio of 250.9.
What is the Repligen stock forecast?
The consensus analyst 12-month price target for Repligen is $189.48, −2.4% from the last close. Of the 12 firms that rated the stock in the last 90 days, 11 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Repligen stock overvalued or undervalued?
On Gekko’s estimate Repligen is overvalued: the Sep 28, 2026 close of $194.09 is 23.8% above Gekko Fair Value of $156.83. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Repligen report earnings next?
Repligen is expected to report on Nov 3, 2026, before the market opens (35 days away). Analysts expect earnings of $0.46 per share on revenue of $206.8M. Repligen beat the earnings estimate in 6 of its last 8 reports, moving 5.6% on average across the report.
What is Repligen’s 52-week high and low?
Repligen’s 52-week high is $198.87 and its 52-week low is $100.99; it closed at $194.09 on Sep 28, 2026, +59.5% over the past year. Over the last five years the shares peaked at $306.98 on Nov 2, 2021.
Is Repligen stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (trend and earnings risk), 1 as mixed (gekkoindex) and 2 as headwinds (fair value and seasonality). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Repligen the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.